KVK Tech has reportedly signed a strategic partnership with Sen-Jam Pharmaceutical to develop, produce, supply, and license oral treatment of COVID-19.

The firms will operate simultaneously with the completion of their Phase II clinical trials to get a comprehensive product in 9 to 12 months. KVK will provide formulation and CMC (chemistry, manufacturing, and controls) for oral therapy.

Jim Iversen, the Chief Executive Officer of Sen-Jam Pharmaceutical, stated that the robust capacity and reputation of KVK Tech to generate billions of capsules and tablets yearly makes it an ideal partner for the company’s oral COVID-19 therapeutics.

Moreover, KVK Tech will strategically invest in Sen-Jam to conclude the overall development activities necessary to offer the CMC package to the FDA (Food and Drug Administration) for submitting an NDA (new drug application).

Sen-Jam will use the CMC work and finished formulation to enter licensing agreements with the CMOs (contracting manufacturing companies) worldwide.

Currently, the company is discussing early-stage talks with different CMOs globally, and the recent agreement with KVK would help the firms to accelerate the advancement of such collaborations.

Kiran Vepuri, the Vice President of Business Development and Brand Marketing at KVK Tech, stated that the company is committed to providing effective, affordable, and safe FDA-approved pharmaceuticals to cater to the needs of customers and assure that patients get access to top-quality medicines as per their requirements.

Vepuri added that Sen-Jam’s impressive team of scientists, innovators, entrepreneurs represent an ideal fit for its culture of introducing life-saving medications to the public at low costs.

In August 2021, Singapore’s Duke-NUS Medical School and Sen-Jam collaborated to unveil a Phase II trial of the SJP-002C COVID-19 investigational treatment in Nepal.

For the record, KVK Tech was founded in 2004 and has become a leader in generics. All its products are made in its advanced facility in Newtown.

Source credit:

https://www.pharmaceutical-technology.com/news/sen-jam-kvk-covid-therapy/